GERN - Geron Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4100
-0.0400 (-2.76%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4500
Open1.4600
Bid1.4100 x 42300
Ask1.4900 x 3200
Day's Range1.4100 - 1.4600
52 Week Range0.9900 - 2.1400
Volume1,282,279
Avg. Volume1,356,438
Market Cap281.687M
Beta (5Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.2500
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.80
  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Jan. 17

    Insiders invest in JPMorgan, Simply Good Foods, Eiger BioPharmaceuticals and Geron Continue reading...

  • Business Wire

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 98,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company.

  • Business Wire

    Geron Announces 2019 Accomplishments and Key Development Priorities for 2020

    Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced 2019 accomplishments and key development priorities for 2020. The Company is currently enrolling patients in the Phase 3 IMerge clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS), and plans to complete enrollment by the end of 2020 with top-line results expected by mid-year 2022.

  • Business Wire

    Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 100,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.

  • Business Wire

    Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis

    Geron Corporation (Nasdaq: GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of imetelstat in patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF. Based on feedback from the meeting, over the coming months Geron plans to submit several Phase 3 trial design proposals in relapsed/refractory MF and to have further discussions with the FDA regarding potential regulatory approval pathways. The Phase 3 trial proposals will be designed to fully characterize the efficacy, safety, and benefit-risk profile of imetelstat treatment for these patients, as well as to confirm the clinical benefit and disease-modifying potential of imetelstat in this indication. Subsequent to these additional discussions with the FDA, and after considering the timing and resources required, as well as other clinical development opportunities for imetelstat, Geron will make a decision regarding potential late-stage development of imetelstat in relapsed/refractory MF.

  • Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
    Zacks

    Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS

    The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.

  • Business Wire

    Geron Reports Two Poster Presentations at American Society of Hematology Annual Meeting

    Geron Corporation (Nasdaq: GERN) today announced that two posters related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida on December 8 and 9. Both posters are available on Geron’s website at www.geron.com/r-d/publications.

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Geron (GERN) Up 2.4% Since Last Earnings Report: Can It Continue?
    Zacks

    Geron (GERN) Up 2.4% Since Last Earnings Report: Can It Continue?

    Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire

    Geron Announces Appointment of New Executive to Focus on Corporate Strategy

    Geron Corporation (GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. “We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external alliances rounds out our executive team’s capabilities,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.

  • Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
    Zacks

    Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?

    Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

  • Thomson Reuters StreetEvents

    Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT

    Q3 2019 Geron Corp Earnings Call

  • Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%
    Zacks

    Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%

    Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.

  • GlobeNewswire

    Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events

    Geron Corporation (GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The Company ended the third quarter with $159.3 million in cash and marketable securities. “Geron has continued to execute on its 2019 development plans,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.

  • GlobeNewswire

    Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase.

  • What Type Of Shareholder Owns Geron Corporation's (NASDAQ:GERN)?
    Simply Wall St.

    What Type Of Shareholder Owns Geron Corporation's (NASDAQ:GERN)?

    A look at the shareholders of Geron Corporation (NASDAQ:GERN) can tell us which group is most powerful. Large...

  • Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline

    Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Geron to Announce Third Quarter Financial Results on November 6, 2019

    Geron Corporation (GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call on Thursday, November 7 at 8:00 a.m. ET to discuss the financial results as well as recent events. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

  • PR Newswire

    Geron (GERN) Alert: Johnson Fistel Launches Investigation into Geron Corporation; Investors Encouraged to Contact Firm

    SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Geron Corporation ("Geron") (GERN) on behalf of investors.  Geron is a biopharmaceutical company. If you lost money, realized or unrealized on your Geron investment, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471.  If emailing, please include a phone number.

  • Geron Starts Enrollment in Phase III MDS Study on Imetelstat
    Zacks

    Geron Starts Enrollment in Phase III MDS Study on Imetelstat

    Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

  • GlobeNewswire

    Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

    Geron Corporation (GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). “Patients with lower risk MDS become dependent on serial transfusions which leads to iron overload, heart and kidney complications, decreases in quality of life and shorter overall survival. Reducing transfusion burden and achieving transfusion independence remain significant medical needs for this disease,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer.

  • Geron's Imetelstat Gets Fast Track Status for Myelofibrosis
    Zacks

    Geron's Imetelstat Gets Fast Track Status for Myelofibrosis

    Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.

  • Benzinga

    The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...